The body mass index has, since the 1970s, dominated routine health screening. For a 5'10" man weighing 180 pounds, BMI lands at 25.9 — borderline overweight. That number, almost the first thing your GP looks at, tells you nothing about where the weight sits. Two men at identical BMI 26 can have wildly different metabolic risk profiles. The simpler measure that has finally become standard in 2026 cardiology — adopted in the American Heart Association's 2025 risk update and the NICE 2025 obesity guideline — is waist-to-height ratio, which captures the abdominal-vs-peripheral fat distribution that BMI ignores.
The 0.5 threshold
The waist-to-height threshold for elevated risk is 0.5. For a 5'10" man (70 inches), that means a 35-inch waist or more. For a 6'0" man, 36 inches. For a 6'2" man, 37 inches. These are not athletic-fit waists — they are the waists most men would report as "still in my jeans". And it is precisely at these numbers that visceral fat — the fat surrounding the liver and intestines, not the subcutaneous fat over the abs — begins to drive insulin resistance, hepatic steatosis and elevated cardiovascular risk.
Why visceral fat does what BMI cannot capture
Subcutaneous fat (under the skin, on the hips, thighs, chest) is metabolically inert in the short term. Visceral fat, which sits between the abdominal organs, is highly metabolically active. It releases free fatty acids directly into the portal vein, drives hepatic gluconeogenesis, and produces inflammatory cytokines (TNF-α, IL-6) at rates roughly four times higher than subcutaneous fat. Two men at BMI 26: one with thin limbs and a protruding belly has potentially three times the visceral fat of the other with the same weight distributed peripherally — and their respective Type 2 diabetes risks differ by a similar factor.
What to actually do at WtHR over 0.5
The interventions are not novel. They are well-established. What is new is the threshold for action — in 2026 cardiology consensus, a man with WtHR ≥ 0.5 should be treated as having moderate-risk metabolic disease until proven otherwise, with intervention applied even in the absence of obvious symptoms. Specifically:
- Fasting insulin (not just fasting glucose) measured at the annual check.
- HbA1c quarterly for the first year of intervention.
- Liver enzymes (ALT specifically) measured to screen for NAFLD.
- Resistance training 3x per week — the single most effective intervention for reducing visceral fat at this stage, more effective than cardiovascular training alone.
- Carbohydrate moderation, not elimination — refined carbohydrate intake under 100g per day, focused on the post-prandial glucose response.
The waist measurement that is correct
The standard is to measure at the level of the umbilicus, after a normal exhale, with the tape parallel to the floor and not compressing the skin. Most men measure at the narrower point above the navel and report a 33-inch waist on what is actually a 36-inch frame. The accurate measurement is unflattering by design — it is meant to capture the metabolic reality, not the trouser size.
If your honest WtHR is 0.55 and your last lipid panel was unremarkable, do not be reassured. The cardiology shift in 2026 reflects two decades of data showing that lipid panels lag the metabolic damage by years. The waist measurement is upstream.